'Pharma Bro' Shkreli Can't Duck Kidney Drug Antitrust Suit Yet

Law360 (April 11, 2019, 8:00 PM EDT) -- Incarcerated “pharma bro” Martin Shkreli and his former company Retrophin Inc. failed to convince a Pennsylvania federal judge to toss a suit accusing them of trying to shut out a generic competitor to the kidney drug Thiola.

Instead, the case will be put on hold for the next 90 days for discovery in order to sort out whether generics maker Spring Pharmaceuticals LLC has standing to sue, the court ruled Tuesday.

“Defendants challenge the factual basis for Spring’s constitutional standing,” the court said in its memorandum. “Therefore, before we may address the merits of Spring’s allegations, we must address whether Spring...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS